Short Interest in Immune Therapeutics Inc (OTCMKTS:IMUN) Decreases By 32.1%

Immune Therapeutics Inc (OTCMKTS:IMUN) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 14,200 shares, a decline of 32.1% from the August 15th total of 20,900 shares. Based on an average daily volume of 1,564,400 shares, the short-interest ratio is presently 0.0 days.

Shares of OTCMKTS:IMUN traded down $0.00 during midday trading on Tuesday, hitting $0.02. 131,500 shares of the stock were exchanged, compared to its average volume of 1,477,628. The business’s 50-day moving average price is $0.02 and its 200 day moving average price is $0.02. Immune Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.05.

About Immune Therapeutics

Immune Therapeutics, Inc, together with its subsidiaries, focuses on the development and commercialization of therapeutic treatments for cancer, human immunodeficiency virus (HIV)/AIDS, and autoimmune and immune disorders in the United States and internationally. It develops methionine enkephalin IRT-101, a small synthetic pentapeptide; and low-dose naltrexone IRT-103, an opioid receptor antagonist that stimulates and/or regulates the immune system to treat a range of autoimmune diseases, including multiple sclerosis; immune disorders, such as Crohn's disease and cancer; and viral infections comprising HIV/AIDS.

Featured Article: What is a Lock-Up Period?

Receive News & Ratings for Immune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.